Anebulo to voluntarily delist from Nasdaq and deregister SEC; Q2 net loss $2.0M

Anebulo Pharmaceuticals, Inc.

Board approved voluntary delisting from Nasdaq and SEC deregistration; expects delisting effective Feb 27, 2026.
Net loss of $2.0M ($0.05/shr) vs $2.5M ($0.09/shr) in same quarter prior year.
Operating expenses flat at $2.6M; cash $9.0M plus $3.0M loan facility available.
Lead candidate selonabant: IV formulation Phase 1 SAD study started Sep 2025; prioritizing pediatric pathway.
Company cites cost savings from ending public reporting obligations as rationale for delisting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.